

RECEIVED  
OIPF

JAN 24 2001

TECH CENTER 1600/2900

ENTERED

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/685,823DATE: 10/20/2000  
TIME: 10:53:33Input Set : A:\P1834US.txt  
Output Set: N:\CRF3\10202000\I685823.raw

3 <110> APPLICANT: Filvaroff, Ellen H.  
 5 <120> TITLE OF INVENTION: Use of IL-17 and LIF Antagonists for the Treatment of  
 6 Cartilagenous Disorders  
 8 <130> FILE REFERENCE: P1834US  
 W--> 10 <140> CURRENT APPLICATION NUMBER: US/09/685,823  
 10 <141> CURRENT FILING DATE: 2000-10-09  
 12 <150> PRIOR APPLICATION NUMBER: US 09/311,832  
 13 <151> PRIOR FILING DATE: 1999-05-14  
 15 <150> PRIOR APPLICATION NUMBER: US 09/380,142  
 16 <151> PRIOR FILING DATE: 1999-08-25  
 18 <150> PRIOR APPLICATION NUMBER: US 60/192,103  
 19 <151> PRIOR FILING DATE: 2000-03-24  
 21 <160> NUMBER OF SEQ ID NOS: 3  
 23 <210> SEQ ID NO: 1  
 24 <211> LENGTH: 9  
 25 <212> TYPE: PRT  
 26 <213> ORGANISM: Artificial sequence  
 28 <220> FEATURE:  
 29 <223> OTHER INFORMATION: Ovalbumin-derived antigenic peptide.  
 31 <400> SEQUENCE: 1  
 32 Ala Arg Gly Ser Val Ile Gly Gly Cys  
 33 1 5  
 35 <210> SEQ ID NO: 2  
 36 <211> LENGTH: 10  
 37 <212> TYPE: PRT  
 38 <213> ORGANISM: Artificial sequence  
 40 <220> FEATURE:  
 41 <223> OTHER INFORMATION: Ovalbumin-derived antigenic peptide.  
 43 <400> SEQUENCE: 2  
 44 Phe Phe Gly Val Gly Ala Lys Lys Gly Cys  
 45 1 5 10  
 47 <210> SEQ ID NO: 3  
 48 <211> LENGTH: 5  
 49 <212> TYPE: PRT  
 50 <213> ORGANISM: Artificial sequence  
 52 <220> FEATURE:  
 53 <223> OTHER INFORMATION: N-terminal aggrecan cleavage fragment.  
 55 <400> SEQUENCE: 3  
 56 Ala Arg Gly Ser Val  
 57 1 5

RECEIVED

JAN 24 2001

TECH CENTER 1600/2900

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/685,823

DATE: 10/20/2000

TIME: 10:53:34

Input Set : A:\P1834US.txt

Output Set: N:\CRF3\10202000\I685823.raw

L:10 M:282 W: Numeric Field Identifier Missing, <140> CURRENT APPLICATION NUMBER: is Added.

RECEIVED

JAN 24 2001

TECH CENTER 10000000